Where the numbers come from
What we know. What we don't
Krevyos publishes figures on the Suite, product, and bounded-context pages. Some are sourced from industry benchmarks; others are directional estimates we believe in but cannot yet cite. This page makes the distinction explicit.
Two rules we follow
- Indicative figures
- Numbers marked indicative are directional. They reflect what we believe a data-first platform delivers in adjacent domains, validated informally against operations comparable to ours. We mark them so a diligence buyer knows to ask for the underlying assumptions in a working session.
- Verified figures
- Numbers without the indicative marker are either industry consensus (EMA / FDA / IQVIA / WHO publications) or measured against Krevyos pilot operations. Each one will be footnoted with its source as we complete this page.
The figures, one by one
Layer 1: The Paradigm
No numerical claims on L1. The argument is qualitative.
Layer 2: The Suite
No numerical claims on L2. The roadmap is qualitative.
Layer 3: Generics product
~85% price erosion within two years of the first generic launch: industry analyst consensus; indicative pending direct citation.
12-18mo lag between a ready dossier and an approved filing: Krevyos benchmark estimate; indicative.
40+ territories per generic product: industry standard practice; not contested.
Layer 4: Bounded contexts
Every per-domain outcome figure (−60% time, +3× parallel filings, ~0 inspection prep, etc.) is currently marked indicative. We are validating each against Krevyos pilot deployments and named-customer comparable data. Until each has its own citation, treat them as directional only.
Question a number?
If you are reviewing Krevyos and a figure feels too high, too low, or unsupported, write to us. We would rather have the conversation than ship copy you cannot defend back to your team.